VJHemOnc Podcast Advances in CAR-T and cellular therapy from EBMT 2020: MSCs, clinical trial updates and gene-edited effector cells
Oct 1, 2020
Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.
Chapters
Transcript
Episode notes
1 2 3 4 5
Introduction
00:00 • 5min
Advances in CAR-T and Mesenchymal Stem Cell Therapy for COVID-19 Pneumonia and Multiple Myeloma
04:45 • 3min
CAR-T Cell Therapy in Difficult-to-Treat Patient Populations
07:23 • 7min
CAR-T Cell Therapy Studies and Real-World Responses
14:13 • 2min
Comparison of T-stinlucil and exocaptogen, and discussion on gene-edited effector cell therapy
16:33 • 4min